Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib open-label study of glofitamab combinations in relapsed/refractory B-cell non-Hodgkin lymphoma
MOH_2021-07-13_009927Phase 2Recruiting
- Sponsor
- Roche
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of glofitamab, atezolizumab, polatuzumab vedotin and obinutuzumab in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (2 arms), sponsored by Roche. Primary endpoint: Recommended Phase II dose confirmation. Started May 2021; status: recruiting.
02
Drugs
glofitamabatezolizumabpolatuzumab vedotinobinutuzumab
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on MOH_2021-07-13_009927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-13_009927.